Étiquette : Syndrome de Lennox-Gastaut

Don’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy, Commentary, M. Scott Perry, 2019

Don’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy - Commentary M. Scott Perry Epilepsy Currents, 2019, Vol. 19, (2), 93-95 DOI: 10.1177/1535759719835671   Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med, 2018, 378, 1888-1897. Background : Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. Methods : In this double-blind, placebo-controlled trial conducted [...]

Lire la suite

EC Clears Cannabidiol for Severe Forms of Epilepsy – Medscape -Deborah Brauser,  Sep 23, 2019.

EC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019   The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]

Lire la suite